ImmuPharma PLC ALIMM-BE:Euronext Brussels

*Data is delayed | EUR
Last | 11:35 AM CET
0.1085quote price arrow down-0.0105 (-8.82%)
Volume
17,772
52 week range
0.10 - 0.22

...

Loading . . .

KEY STATS

  • Open0.119
  • Day High0.119
  • Day Low0.1085
  • Prev Close0.119
  • 52 Week High0.22
  • 52 Week High Date05/21/20
  • 52 Week Low0.10
  • 52 Week Low Date03/18/20
  • Market Cap20.85M
  • Shares Out167.36M
  • 10 Day Average Volume66,469.9
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-27.67

RATIOS/PROFITABILITY

  • EPS (TTM)-0.03
  • P/E (TTM)-3.26
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest ImmuPharma PLC News

There is no recent news for this security.

Latest ALIMM-BE News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's...
Timothy McCarthy
Non-Executive Chairman
Dimitri Dimitriou
Chief Executive Officer
Robert Zimmer M.D., Ph.D.
President
Tracy Weimar
Vice President - Finance
Address
52 Grosvenor Gardens
London
SW1W 0AU
United Kingdom